Entellus Medical Inc. (NASDAQ:ENTL)’s share price shot up 4.1% on Friday . The stock traded as high as $19.65 and last traded at $19.52, with a volume of 70,194 shares. The stock had previously closed at $18.76.

Several research firms recently weighed in on ENTL. BTIG Research reissued a “buy” rating on shares of Entellus Medical in a research report on Wednesday, June 29th. Zacks Investment Research raised Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, August 8th. Canaccord Genuity reissued a “buy” rating and set a $23.00 price objective on shares of Entellus Medical in a research report on Friday, August 5th. Finally, Bank of America Corp. reissued a “buy” rating on shares of Entellus Medical in a research report on Monday, July 18th. Six investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $23.00.

The stock has a 50-day moving average price of $18.34 and a 200-day moving average price of $17.37. The stock’s market capitalization is $367.93 million.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.08. During the same quarter in the prior year, the company earned ($0.15) earnings per share. The company had revenue of $18.73 million for the quarter, compared to analyst estimates of $18.48 million. Entellus Medical’s revenue for the quarter was up 23.3% compared to the same quarter last year. On average, equities analysts forecast that Entellus Medical Inc. will post ($1.23) earnings per share for the current year.

In other news, VP Timothy B. Petrick sold 3,000 shares of the stock in a transaction on Monday, July 18th. The stock was sold at an average price of $18.15, for a total value of $54,450.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Brian E. Farley sold 17,006 shares of the stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $19.33, for a total value of $328,725.98. Following the completion of the transaction, the director now owns 560,265 shares of the company’s stock, valued at $10,829,922.45. The disclosure for this sale can be found here.

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.